Source comparison
PT-141 Libido Enhancement Complete Guide 2026: Comparison of Sexual Dysfunction Treatments
PT-141 (bremelanotide) MC4R agonist. Activates hypothalamic arousal circuits centrally Premenopausal women with HSDD; off-label use in men exploring central arousal enhancement 1.75mg subcutaneous injection 45 min before activity, max once per 24 hours 30–45 m
This comparison does not assign a generated winner or score.
- PT-141 (bremelanotide)
- MC4R agonist. Activates hypothalamic arousal circuits centrally
- Premenopausal women with HSDD; off-label use in men exploring central arousal enhancement
- 1.75mg subcutaneous injection 45 min before activity, max once per 24 hours
- 30–45 min, effects last 6–12 hours
- Nausea (40%), flushing (20%), headache (11%), transient BP increase
- Effective for desire deficits, not performance issues; requires screening for cardiovascular risk
- Sildenafil (Viagra)
- PDE5 inhibitor. Sustains nitric oxide signaling in genital smooth muscle
- Men with erectile dysfunction; off-label use in women for genital arousal disorders
- 25–100mg oral, 30–60 min before activity
- 30–60 min, effects last 4–6 hours
- Headache (16%), flushing (10%), nasal congestion, visual disturbances (rare)
- Facilitates erection in response to arousal; does not create desire
- Flibanserin (Addyi)
- 5-HT1A agonist / 5-HT2A antagonist. Modulates serotonin and dopamine balance
- Premenopausal women with HSDD
- 100mg oral daily at bedtime
- Effects accumulate over 4–8 weeks
- Dizziness (11%), somnolence (11%), nausea, hypotension with alcohol
- Daily medication, not on-demand; modest efficacy, significant dropout due to CNS effects
- Testosterone therapy
- Androgen replacement. Increases baseline libido, energy, and genital sensitivity
- Postmenopausal women with low testosterone; men with hypogonadism
- Transdermal patch or gel, daily application
- Effects build over weeks to months
- Acne, hair growth, voice changes, lipid alterations, cardiovascular risk (contested)
- Effective for hormonal deficits; not FDA-approved for female HSDD; requires monitoring